Apologies for light posting as of late. I’ve been buried deep in revisions to Building Biotechnology and prepping for an upcoming talk. Writing is coming to a close, so soon I’ll be looking for external reviewers and case study contributions. For those of you attending BIO 2008, I’ll be presenting in a session on trends […]
The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract of each article: Volume 14, Issue 2 Editorial Editorial PDF Yali Friedman Articles Export compliance for life sciences PDF John Avellanet A new approach to improve technology commercialisation in university medical schools PDF […]
Courtesy of DrugPatentWatch.com: Drug Patent Expirations in April 2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ACTINEX Univ Az Cancer Ctr masoprocol 4,695,590 APR 17,2008 ACTINEX Univ Az Cancer Ctr masoprocol 5,008,294 APR 15,2008 ESTROSTEP 21 Warner Chilcott ethinyl estradiol; norethindrone acetate 5,010,070 APR 23,2008 ESTROSTEP FE […]
Posting has been light lately — I’ve been working hard on revising Building Biotechnology. Off to the NIH next week to give my talk on biotechnology entrepreneurship. Upcoming talk at Johns Hopkins Carey School of Business on a multifaceted dissection of the biotechnology industry.
Two new biotechnology books: I’m proud to announce two new books featuring international best practices in biotechnology business development and biotechnology education. These new books respectively empower industry leaders operating in the dynamic biotechnology industry, and help address the global shortage of skilled biotechnology workers. [AMAZONPRODUCT=0973467673] First Edition, March 2008 Perfect Bound, 342 pages, US$74.95 […]
Courtesy of DrugPatentWatch.com: Drug Patent Expirations in March 2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration CARDIZEM CD Biovail diltiazem hydrochloride 5,002,776 MAR 26,2008 CARDURA XL Pfizer doxazosin mesylate 4,837,111 MAR 21,2008 CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER Bayer Pharms ciprofloxacin 4,957,922 MAR 18,2008 CIPRO IN […]
Guest content from John Avellanet, managing director and principal of Cerulean Associates: Follow-on biologics are a foregone conclusion in the US. Too much money is at stake. The more difficult discussion starts with how to prepare your company to compete. Science Succumbs to Dollars The financial pull on reimbursement organizations and the constituent push on […]
Browsing around the Biotechnology Industry Organization site late last night, I was surprised to find that BIO’s press release section had been hacked. No evidence of tampering elsewhere on the site, but all the news releases have been tagged by the hackers.
I’ll be at Rutgers on February 29th, giving a talk on biotechnology entrepreneurship. My objective is to dispel the popular notions about how biotechnology entrepreneurship occurs, and to provide case studies demonstrating the diversity of methods by which biotechnology entrepreneurs start and build their businesses. I’ll also provide some case studies of significant mis-steps, with […]
The following appeal for generic biologic legislation was sent in from Insmed via youtube. I’ve posted previously on the challenges of developing a framework for generic biologic approvals and questioned how much we can really expect to save. In the editorial for the upcoming issue of the Journal of Commercial Biotechnology, I argue that the […]